Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2.

Karin M, Dhar D.

Carcinogenesis. 2016 Jun;37(6):541-6. doi: 10.1093/carcin/bgw060. Epub 2016 May 4. Review.

2.

Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma.

Bartolini D, Dallaglio K, Torquato P, Piroddi M, Galli F.

Transl Res. 2018 Mar;193:54-71. doi: 10.1016/j.trsl.2017.11.007. Epub 2017 Nov 29. Review.

PMID:
29274776
3.

Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Zoller H, Tilg H.

Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23. Review.

PMID:
26907206
4.

Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis.

Inoue-Yamauchi A, Itagaki H, Oda H.

Carcinogenesis. 2018 Jan 12;39(1):28-35. doi: 10.1093/carcin/bgx112.

5.

Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice.

Yi X, Long L, Yang C, Lu Y, Cheng M.

PLoS One. 2014 Apr 1;9(4):e93599. doi: 10.1371/journal.pone.0093599. eCollection 2014.

6.

Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.

Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, Ketterer S, Terracciano L, Heim MH.

Carcinogenesis. 2014 Jan;35(1):114-22. doi: 10.1093/carcin/bgt258. Epub 2013 Jul 29.

PMID:
23901063
7.

Molecular mechanism of liver cancer.

Pan H, Fu X, Huang W.

Anticancer Agents Med Chem. 2011 Jul;11(6):493-9. Review.

PMID:
21554201
8.

Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice.

Ip BC, Hu KQ, Liu C, Smith DE, Obin MS, Ausman LM, Wang XD.

Cancer Prev Res (Phila). 2013 Dec;6(12):1304-16. doi: 10.1158/1940-6207.CAPR-13-0178. Epub 2013 Oct 1.

9.

Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.

Rappa F, Greco A, Podrini C, Cappello F, Foti M, Bourgoin L, Peyrou M, Marino A, Scibetta N, Williams R, Mazzoccoli G, Federici M, Pazienza V, Vinciguerra M.

PLoS One. 2013;8(1):e54458. doi: 10.1371/journal.pone.0054458. Epub 2013 Jan 23. Erratum in: PLoS One. 2013;8(3). doi:10.1371/annotation/b456329c-02fa-4055-afb8-2090cec17da6.

10.

Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.

Marhenke S, Lamlé J, Buitrago-Molina LE, Cañón JM, Geffers R, Finegold M, Sporn M, Yamamoto M, Manns MP, Grompe M, Vogel A.

Hepatology. 2008 Aug;48(2):487-96. doi: 10.1002/hep.22391.

PMID:
18666252
11.

Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes.

Pilar Valdecantos M, Prieto-Hontoria PL, Pardo V, Módol T, Santamaría B, Weber M, Herrero L, Serra D, Muntané J, Cuadrado A, Moreno-Aliaga MJ, Alfredo Martínez J, Valverde ÁM.

Free Radic Biol Med. 2015 Jul;84:263-278. doi: 10.1016/j.freeradbiomed.2015.03.019. Epub 2015 Apr 1.

PMID:
25841776
12.

CCAAT/enhancer-binding protein homologous (CHOP) protein promotes carcinogenesis in the DEN-induced hepatocellular carcinoma model.

Scaiewicz V, Nahmias A, Chung RT, Mueller T, Tirosh B, Shibolet O.

PLoS One. 2013 Dec 5;8(12):e81065. doi: 10.1371/journal.pone.0081065. eCollection 2013.

13.
14.

Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice.

Li X, Liu C, Ip BC, Hu KQ, Smith DE, Greenberg AS, Wang XD.

J Exp Clin Cancer Res. 2015 Nov 11;34:138. doi: 10.1186/s13046-015-0254-2.

15.

CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.

Kakehashi A, Ishii N, Sugihara E, Gi M, Saya H, Wanibuchi H.

Cancer Sci. 2016 May;107(5):609-18. doi: 10.1111/cas.12908. Epub 2016 Mar 28.

16.

Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice.

Teng YC, Neo JC, Wu JC, Chen YF, Kao CH, Tsai TF.

J Pathol. 2017 Mar;241(4):463-474. doi: 10.1002/path.4850. Epub 2017 Jan 5.

PMID:
27868197
17.

Lack of nrf2 results in progression of proliferative lesions to neoplasms induced by long-term exposure to non-genotoxic hepatocarcinogens involving oxidative stress.

Tasaki M, Kuroiwa Y, Inoue T, Hibi D, Matsushita K, Kijima A, Maruyama S, Nishikawa A, Umemura T.

Exp Toxicol Pathol. 2014 Jan;66(1):19-26. doi: 10.1016/j.etp.2013.07.003. Epub 2013 Aug 27.

PMID:
23988840
18.

Influence of sex and developmental stage on acute hepatotoxic and inflammatory responses to liver procarcinogens in the mouse.

Hanna D, Riedmaier AE, Sugamori KS, Grant DM.

Toxicology. 2016 Dec 12;373:30-40. doi: 10.1016/j.tox.2016.10.006. Epub 2016 Oct 13.

PMID:
27746196
19.

Black currant anthocyanins abrogate oxidative stress through Nrf2- mediated antioxidant mechanisms in a rat model of hepatocellular carcinoma.

Thoppil RJ, Bhatia D, Barnes KF, Haznagy-Radnai E, Hohmann J, Darvesh AS, Bishayee A.

Curr Cancer Drug Targets. 2012 Nov 1;12(9):1244-57.

PMID:
22873220
20.

Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma.

Vandewynckel YP, Laukens D, Devisscher L, Bogaerts E, Paridaens A, Van den Bussche A, Raevens S, Verhelst X, Van Steenkiste C, Jonckx B, Libbrecht L, Geerts A, Carmeliet P, Van Vlierberghe H.

BMC Cancer. 2016 Jan 11;16:9. doi: 10.1186/s12885-015-1990-6.

Supplemental Content

Support Center